<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Pregnancy loss, often recurrent, is one of the most important clinical manifestations associated with the <z:e sem="disease" ids="C0409980" disease_type="Disease or Syndrome" abbrv="">primary antiphospholipid syndrome</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>In these cases, pregnancy wastage is related to the presence of <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo>, namely <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> and anticardiolipin antibodies, but patients do not have features of <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> or any other well-defined <z:hpo ids='HP_0002960'>autoimmune disease</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>We report here on the outcome of 21 consecutive pregnancies in 18 patients with the syndrome who were treated with low-dose aspirin (100 mg/day) from 1 month before attempting conception and throughout the pregnancy </plain></SENT>
<SENT sid="3" pm="."><plain>Low-dose <z:chebi fb="0" ids="8382">prednisone</z:chebi> (15-30 mg/day) was added for potentially non-obstetric (autoimmune-related) reasons in six pregnancies </plain></SENT>
<SENT sid="4" pm="."><plain>Patients were monitored as having <z:e sem="disease" ids="C0242786" disease_type="Disease or Syndrome" abbrv="">high-risk pregnancies</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Prior to therapy, the rate of live-born babies was 6.1% (46 previous fetal losses and three live-born babies), and after therapy, it was 90.5% (21 pregnancies and 19 live-born babies) </plain></SENT>
<SENT sid="6" pm="."><plain>Pre-term delivery due to maternal or fetal indications was required in 15% (3/20) of the viable pregnancies </plain></SENT>
<SENT sid="7" pm="."><plain>Except for <z:e sem="disease" ids="C0728731" disease_type="Disease or Syndrome" abbrv="">prematurity</z:e> (20% of viable pregnancies) and its potential associated complications, there were no significant adverse effects to either mothers or babies </plain></SENT>
<SENT sid="8" pm="."><plain>Our treatment modality is advocated for prevention of pregnancy losses in patients with the 'obstetric' <z:e sem="disease" ids="C0409980" disease_type="Disease or Syndrome" abbrv="">primary antiphospholipid syndrome</z:e> </plain></SENT>
</text></document>